NCT04245514View on ClinicalTrials.gov

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2031

Conditions
Non-small Cell Lung CancerNSCLC
Interventions
DRUG

Durvalumab

Immunotherapy

RADIATION

Radiotherapy

Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d

Trial Locations (13)

1211

Hôpitaux Universitaires de Genève, Geneva

3010

Inselspital, Bern

3600

Regionalspital Thun, Thun

4016

St. Claraspital Basel, Basel

4031

Universitaetsspital Basel, Basel

5404

Kantonsspital Baden, Baden

6500

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona

8063

Stadtspital Triemli, Zurich

8091

Universitätsspital Zuerich, Zurich

72076

Universitätsklinikum Tübingen, Tübingen

CH-5001

Kantonsspital Aarau, Aarau

CH-7000

Kantonsspital Graubuenden, Chur

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER